Skip to main content

25-02-2021 | ASCO GU 2021 | Conference coverage | Video

Cabozantinib benefit for metastatic papillary RCC demonstrated

Sumanta Pal provides an overview of the phase 2 SWOG 1500 study pitting the MET inhibitors cabozantinib, crizotinib, and savolitinib against sunitinib for the treatment of metastatic papillary renal cell carcinoma (3:49).

Read transcript

Image Credits